EGFR and glioblastoma: Approximately 20–30% of GBM patients have tumors that harbor an in-frame deletion of exons 2–7 coding for an isoform of EGFR, named EGFR variant III (EGFRvIII), which has been used as the target antigen in pre-clinical models and clinical trials.